What is Form Bio?
Form Bio operates at the intersection of artificial intelligence and genomic science, providing a sophisticated platform designed to streamline the development of genetic therapies. The company specializes in the optimization of AAV vectors and the enhancement of CRISPR accuracy, addressing some of the most persistent bottlenecks in genome engineering. By offering a suite of tools for vector design, payload optimization, and protein engineering, Form Bio enables biotechnology firms to improve the safety and efficacy of their therapeutic pipelines. Their market position is defined by a commitment to improving genome integrity, effectively serving as a technological backbone for organizations navigating the complex regulatory and scientific landscape of modern genetic medicine.
How much funding has Form Bio raised?
Form Bio has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2022): $30M with participation from Thomas Tull and JAZZ Venture Partners
Key Investors in Form Bio
Thomas Tull
A prominent investor and entrepreneur known for backing high-growth technology and media ventures with a focus on transformative innovation.
JAZZ Venture Partners
A venture capital firm that invests in technologies aimed at enhancing human performance across various sectors, including healthcare, wellness, and consumer markets.
What's next for Form Bio?
With this major strategic investment, Form Bio is poised to scale its computational infrastructure and expand its service offerings within the global biotechnology sector. The company's roadmap likely involves deepening its AI capabilities to further refine genome editing precision and broadening its collaborative reach with clinical-stage partners. As the demand for safer, more targeted genetic interventions continues to rise, Form Bio is well-positioned to capitalize on the shift toward data-centric drug discovery. Future growth will likely focus on enhancing the scalability of their platform to support larger, more complex therapeutic programs, ensuring that their AI-driven solutions remain at the forefront of the genetic medicine revolution.
See full Form Bio company page
